- Home
- HSCS vs CLDI Comparison
HSCS vs CLDI Comparison
Compare HSCS & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSCS | CLDI |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HSCS | CLDI |
|---|---|---|
| Price | $1.70 | $0.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 22.5K | ★ 1.6M |
| Earning Date | 03-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $0.16 |
| 52 Week High | $6.47 | $7.32 |
Technical Indicators
Market Signals| Indicator | HSCS | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 38.34 |
| Support Level | N/A | $0.16 |
| Resistance Level | $2.16 | $0.30 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 39.84 | 43.78 |
Price Performance
Historical ComparisonAbout HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.